Health ❯ Pharmaceuticals

Cancer Treatment

Drug Development Immunotherapy Prostate Cancer mRNA Technology mRNA Therapies FDA Regulations Clinical Trials Autoimmune Diseases Drug Importation Trastuzumab Rezetecan Cancer Vaccine Multiple Sclerosis Rare Diseases Tumor Diseases Drug Pipeline Leucovorin Research and Development Monoclonal Antibodies AI Applications Letrozole Corporate Ethics Myelofibrosis Drug Diversion Generic Drugs Keytruda Breast Cancer Lung Cancer Venetoclax

Lilly and InnoCare Agree Discovery Pact Valued at Up to $3.35 Billion

The deal could speed discovery of new cancer and autoimmune therapies by funding early work under a milestone-based payment structure.

Venetoclax Reduces Intact SIV Reservoir in Macaques

ImmunityBio Investors Face May 26 Deadline in Securities Class Action Over FDA Ad Rebuke

Lilly to Acquire Ajax Therapeutics in Up to $2.3 Billion Blood Cancer Deal

ImmunityBio Investors Urged to Seek Lead Role in Suit After FDA Rebuke Over Anktiva Ads

Law Firms Urge Telix Investors Ahead of Lead‑Plaintiff Deadline in Securities Class Action

Law Firms Urge Telix Investors To Seek Lead Role by Jan. 9 in Securities Class Action

Telix Securities Class Action Draws Flurry of Investor Notices Ahead of Lead-Plaintiff Deadline

Multiple Firms File Securities Class Actions Against Telix in Indiana Federal Court Over Prostate Cancer Program Disclosures

Recursion Soars on Heavy Volume as Investors Eye CEO’s AI Conference Appearance

Eli Lilly Picks Virginia for $5 Billion Bioconjugate Plant, First of Four New U.S. Sites